Myeloproliferative Neoplasm
144 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by PV Reporter from PARP Inhibitors Cancer Review
Scoop.it!

Mira Dx Ongoing Research | Genetic Testing for Breast and Ovarian Cancer

Mira Dx Ongoing Research | Genetic Testing for Breast and Ovarian Cancer | Myeloproliferative Neoplasm | Scoop.it
MiraDx is committed to discovering meaningful ways to better treat cancer in patients with mutations like and including the KRAS-variant We are working to discover answers through our research programs in the following areas:



Via Krishan Maggon
PV Reporter's insight:
List of significant published research related to the KRAS-variant: The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905 Lee LJ, et al. PLoS One. 2014 Apr 14;9(4):e94167. Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7 Levels Crowley EH et al. Hum Mutat. 2013 Nov 26. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients Sebio A et al. Pharmacogenet Genomics. 2013 Mar;23(3):142-7. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC–letter Ryan BM, et al. Clin Cancer Res. 2012 Jun 15;18(12):3487-8; author reply 3489.
more...
Krishan Maggon 's curator insight, March 22, 5:33 AM
List of significant published research related to the KRAS-variant: The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905 Lee LJ, et al. PLoS One. 2014 Apr 14;9(4):e94167. Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7 Levels Crowley EH et al. Hum Mutat. 2013 Nov 26. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients Sebio A et al. Pharmacogenet Genomics. 2013 Mar;23(3):142-7. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC–letter Ryan BM, et al. Clin Cancer Res. 2012 Jun 15;18(12):3487-8; author reply 3489.
Rescooped by PV Reporter from Melanoma BRAF Inhibitors Review
Scoop.it!

Cancer: Reshaping the cancer clinic : Nature : Nature Publishing Group

Cancer: Reshaping the cancer clinic : Nature : Nature Publishing Group | Myeloproliferative Neoplasm | Scoop.it
Big data's war on cancer is still in the early stages, but the front line is advancing.

 

The Cancer Genome Atlas, which catalogues cancer mutations, contains some 2.5 million gigabytes of data. This giant project, run by the US National Institutes of Health, has vastly improved our understanding of various forms of cancer — but it holds relatively little information on the clinical experience of the patients who supplied the samples.

At the other end of the cancer treatment chain, electronic health records contain a wealth of case-specific information that could be used to improve cancer care. But more often than not, such records are isolated in individual hospitals and medical practices. As a result, “most patient experiences are lost to research”, says Clifford Hudis, an oncologist who specializes in breast cancer at the Memorial Sloan Kettering Cancer Center in New York.

In an effort to improve cancer treatment, Hudis and many others are now collaborating on efforts to bring together and make sense of the big data that emerge from research, patient care and clinical trials. Opportunities for big data extend across most areas of medicine, but “cancer is leading the way”, says Lynn Etheredge, a health-care consultant based in Chevy Chase, Maryland. But the ubiquity, variety and lethality of cancer mean that there are plenty of barriers as well as breakthroughs.


Via Krishan Maggon
PV Reporter's insight:

My latest article on PV Reporter talks about a similar strategy, in utilizing patient data that will be readily volunteered, it's there for the asking - http://www.pvreporter.com/an-opportunity-to-improve-measurement-of-health-related-quality-of-life-symptoms-using-mpn-patient-reported-outcomes-using-an-internet-based-tool/

more...
Krishan Maggon 's curator insight, November 5, 2015 6:50 AM
Cancer: Reshaping the cancer clinicCharlie SchmidtNature 527, S10–S11 (05 November 2015) doi:10.1038/527S10aPublished online 04 November 2015
 
 
Rescooped by PV Reporter from PARP Inhibitors Cancer Review
Scoop.it!

FDA approves Jakafi to treat patients with a chronic type of bone marrow disease

The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.

Via Krishan Maggon
PV Reporter's insight:

The First drug ever approved for Polycythemia Vera, PV!!

more...
Krishan Maggon 's curator insight, December 5, 2014 1:45 AM

The approval for this new indication will propel Jakafi to reach blockbuster sales within a year.

 

The FDA reviewedJakafi’s use for polycythemia vera under the agency’s priority review program because, at the time the application was submitted, the drug demonstrated the potential to be a significant improvement in safety or effectiveness over available therapy in the treatment of a serious condition. Priority review provides an expedited review of a drug’s application. Jakafi also received orphan product designation because it is intended to treat a rare disease.

 

In 2011, the FDA approved Jakafi for treatment of patients with another bone marrow disorder, intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Scooped by PV Reporter
Scoop.it!

Promedior Gets FDA Orphan Status For Myelofibrosis Drug

Promedior Gets FDA Orphan Status For Myelofibrosis Drug | Myeloproliferative Neoplasm | Scoop.it
Clinical stage biotech firm Promedior announced that its drug PRM-151 has been granted Orphan Drug status by the U.S. Food and Drug Administration...
PV Reporter's insight:

(2) Drugs moving forward for Myelofibrosis, Promedior's PRM-151 and CTI BioPharma's Pacritinib.

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Advances in Understanding and Treating MPNs

Dr. Srdan Verstovsek, a world-renowned researcher from MD Anderson Cancer Center, explores what he describes as "unprecedented developments" in the understanding of myeloproliferative neoplasms...
PV Reporter's insight:

Combo studies with JAK2 inhibitors are taking place, anti fibrotic drugs are being studied for MF. PV patients suffer from constitution symptoms, large spleen and other issues, JAK2 inhibitors are under study for PV for patients who don't do well with HU or IFN. ET patients responding well to IFN.

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Ruxolitinib Improves Over Best Available Therapy in Polycythemia Vera - Cancer Network

Ruxolitinib Improves Over Best Available Therapy in Polycythemia Vera - Cancer Network | Myeloproliferative Neoplasm | Scoop.it
Ruxolitinib Improves Over Best Available Therapy in Polycythemia Vera Cancer Network PV is a myeloproliferative neoplasm characterized by debilitating symptoms and poor quality of life; there is also potential for life-threatening cardiovascular...
PV Reporter's insight:

Ruxolitinib (Jakafi) is one step closer to FDA approval for Polycythemia Vera patients.

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN) [A ...

CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN) [A ... | Myeloproliferative Neoplasm | Scoop.it
The new CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN) assay is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered on patients with clinical suspicion ...
PV Reporter's insight:

This important new discovery, CALR mutation, is now available for analysis testing at Mayo Clinic. 

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Myeloproliferative Neoplasm Videos - 2014 | PV Reporter | Blood Cancer

Myeloproliferative Neoplasm Videos - 2014 | PV Reporter | Blood Cancer | Myeloproliferative Neoplasm | Scoop.it
Myeloproliferative Neoplasm Videos by Patient Power Patient Power has created a “best of breed” library of video programs that continues to expand as they attend medical conferences and produce town meetings for patients around the world. Top medical experts are featured as they discuss issues pertinent to all MPN patients. Areas of discussion include the latest drug …
more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Ruxolitinib for the treatment of myelofibr... [Pharmacoeconomics. 2013] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Polycythemia Vera Patient Announces Successful Launch of a Comprehensive, Patient Focused Site for the Myeloproliferative Neoplasm Community

Press Release issued Mar 17, 2014: When 47-year-old David Wallace was diagnosed with Polycythemia Vera in 2009, he was puzzled by this rare blood cancer.
more...
No comment yet.
Rescooped by PV Reporter from "Patient empowerment through health education, health literacy, e-health literacy, public health promotion, narrative tools & art | e-patients | Patient expertise | Patient advocacy | Shared health decision making" by VAB Traductions
Scoop.it!

How Patients are Helping Change Medical Journals: BMJ’s Tessa Richards at MedX 2015 | e-Patients.net

How Patients are Helping Change Medical Journals: BMJ’s Tessa Richards at MedX 2015 | e-Patients.net | Myeloproliferative Neoplasm | Scoop.it

"It’s not just that the great e-patient awakening is happening and spreading; the highest levels of the medical establishment have endorsed the shift. In 2012 the Institute of Medicine wrote that the future of medicine must include “Patient/Clinician Partnerships” and explicitly said “Empowered, engaged patients.”


Via VAB Traductions
PV Reporter's insight:

If you have an MPN, become educated - informed and you will be your own best #advocate!

more...
No comment yet.
Rescooped by PV Reporter from Healthcare Digital Marketing
Scoop.it!

Sense.ly’s uses a virtual nurse named Molly, who acts as the provider’s point of contact for patients.

Sense.ly’s uses a virtual nurse named Molly, who acts as the provider’s point of contact for patients. | Myeloproliferative Neoplasm | Scoop.it

Sense.ly has developed an interactive, animated nurse avatar called Molly, which provides follow-up care to patients, focusing mostly on those that have chronic diseases. Using gesture capture based on Microsoft’s Kinect as well as a Nuance-powered speech recognition engine, Molly can analyze a patient’s condition and provide insights into what steps patients should improve their health. The program is offered under a Software as a Service business model, which means providers can deploy it either as a kiosk or on a tablet, though different modalities have different functionality with regards to the Kinect.


Via Marc Phippen
PV Reporter's insight:

This the future of healthcare, telemedicine....welcome to 2016!

more...
No comment yet.
Rescooped by PV Reporter from Doctors Hub
Scoop.it!

Medical Professionals Can Now “Learn from Smart Patients”

Medical Professionals Can Now “Learn from Smart Patients” | Myeloproliferative Neoplasm | Scoop.it

We're launching Learn from Smart Patients, a new website and a new program where we are working with medical centers and training programs, to create learning materials for them based on conversations in Smart Patients. Curated conversations are de-identified and used with patient permission.

 


Via Philippe Marchal
PV Reporter's insight:

This is part of a growing trend, as smart patients live our illness daily. We share treatment tips (sometimes natural or OTC) on social media that help some patients. Nice to see medical professionals get involved learning from patients.

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis - Drugs.com MedNews

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis - Drugs.com MedNews | Myeloproliferative Neoplasm | Scoop.it
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S.
PV Reporter's insight:

Fast track designation for Pacritinib (JAK2 inhibitor) for Myelofibrosis.

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

2014 PERSIST-1 Trial is now recruiting for Phase 3

2014 PERSIST-1 Trial is now recruiting for Phase 3 | Myeloproliferative Neoplasm | Scoop.it
A randomized, controlled Phase 3 study of oral Pacritinib vs. best available therapy for patients with myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis is anticipated to be closing soon.
PV Reporter's insight:

Pacritinib moves forward on Phase 3 trial for MF.  Another new drug in phase 3 stage is encouraging for all MPN patients!

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

FDA lifts partial hold on study testing Geron's drug, shares jump - Reuters

ThFDA lifts partial hold on study testing Geron's drug, shares jump Reuters It came a week after the regulator ordered Geron to cease company-sponsored trials of the drug evaluating its use in thrombocythemia and multiple myeloma, two forms of blood...

PV Reporter's insight:

This is good news for MF patients!  The hold remains in place for PV and ET patients.

more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms, Expert Review of Hematology, Informa Healthcare

Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms, Expert Review of Hematology, Informa Healthcare | Myeloproliferative Neoplasm | Scoop.it
Check out this FREE Perspective on the impact of JAK inhibitors upon comorbidities in #myelofibrosis - http://t.co/n1PLdGARbV
more...
No comment yet.
Scooped by PV Reporter
Scoop.it!

Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in ... - Wall Street Journal

Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in ... - Wall Street Journal | Myeloproliferative Neoplasm | Scoop.it
Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in ...
more...
No comment yet.
Rescooped by PV Reporter from "Patient empowerment through health education, health literacy, e-health literacy, public health promotion, narrative tools & art | e-patients | Patient expertise | Patient advocacy | Shared health decision making" by VAB Traductions
Scoop.it!

Patient advocacy influential in drug development, says panel

Patient advocacy influential in drug development, says panel | Myeloproliferative Neoplasm | Scoop.it
Patient advocacy groups are an increasingly valuable resource for pharma manufacturers and FDA throughout the drug development process, since they provide, among other things, a crucial perspective, according to a New York Pharma Forum panel last...

Via VAB Traductions
PV Reporter's insight:

Patient advocacy influential in drug development - http://bit.ly/OKGM02 #patient #cancer #drug

more...
Tambre Leighn's curator insight, March 23, 2014 11:13 AM

Advocacy DOES make a difference.  Through advocacy, we raise awareness, educate and empower.  Who better than those directly using pharma solutions to address an illness than the patients.  

 

As a coach, I've seen over and over the healing value of patients taking an advocacy role - be it by taking part in a Relay for Life, speaking out to lawmakers or starting non-profits to raise funds for a cause near and dear to them.

 

We must speak up to create the changes we believe will improve the quality of life for survivors, caregivers and their healthcare practitioners.  How will you raise your voice?  

Tambre Leighn's curator insight, March 23, 2014 11:14 AM

Advocacy DOES make a difference.  Through advocacy, we raise awareness, educate and empower.  Who better than those directly using pharma solutions to address an illness than the patients.  

 

As a coach, I've seen over and over the healing value of patients taking an advocacy role - be it by taking part in a Relay for Life, speaking out to lawmakers or starting non-profits to raise funds for a cause near and dear to them.

 

We must speak up to create the changes we believe will improve the quality of life for survivors, caregivers and their healthcare practitioners.  How will you raise your voice?  

Scooped by PV Reporter
Scoop.it!

Novartis drug Jakavi® associated with significant clinical benefits to patients with Myelofibrosis | Biotechnology Focus

Novartis drug Jakavi® associated with significant clinical benefits to patients with Myelofibrosis | Biotechnology Focus | Myeloproliferative Neoplasm | Scoop.it
Novartis drug Jakavi® associated with significant clinical benefits to patients with Myelofibrosis following Phase 3 trial (Novartis' Jakavi drug sees significant clinical benefits for patients w.
more...
No comment yet.